Publications by authors named "Laura D'Errico"
Article Synopsis
- Trastuzumab is the only approved targeted therapy for patients with HER2-amplified metastatic gastric cancer (GC), but it only provides long-term benefits for a small number of patients.
- A study was conducted to test various HER2-targeted treatments in gastric cancer tumors with high HER2 amplification, using patient-derived xenografts.
- The results showed that combining trastuzumab with other treatments like pertuzumab or lapatinib resulted in significantly better responses, suggesting that a stronger therapeutic approach could benefit patients with HER2-driven gastric tumors despite some previous clinical trial failures.
Article Synopsis
- Gastric and gastroesophageal adenocarcinomas are a major cause of cancer-related deaths, with advanced cases showing poor treatment outcomes, especially when using anti-EGFR agents without molecular selection.
- Research included four patient cohorts and preclinical studies using patient-derived xenografts, revealing that EGFR amplification correlates with worse prognosis and treatment response.
- The study suggests that combining EGFR inhibitors with other therapies, like mTOR inhibitors, can enhance treatment effectiveness and overcome resistance in specific cancer cases.
Purpose: A growing number of studies on animal models have demonstrated that some ocular diseases are the result of the interaction between hyalocytes and the ocular inflammatory setting. Endogenous and exogenous substances might alter the structure and behavior of hyalocytes that can contribute to the pathogenesis of some ocular diseases. Obtaining primary cultures of human hyalocytes could help understand the role of these cells in response to different treatments.
View Article and Find Full Text PDFArticle Synopsis
- Gastric cancer is the third leading cause of cancer deaths globally, and despite treatment advancements, patients with advanced stages have poor outcomes, highlighting the need for new therapeutic targets.
- Researchers developed a comprehensive platform of gastric cancer models, including 100 patient-derived xenografts (PDX), primary cell lines, and organoids, classified by various molecular and histological traits.
- Analysis of the PDX models revealed a specific microsatellite instability (MSI) signature that helps identify a subgroup of microsatellite stable (MSS) patients with better prognosis, suggesting new avenues for treatment and target validation.